Friday, July 16, 2021

7:30 – 7:40 AM          Welcome & Introductions

Benjamin M. Parsons, DO, President, Wisconsin Association of Hematology and Oncology

7:40 – 8:20 AM          Federal and State Legislative Update

Kristin Stuart, Associate Director, Congressional Affairs, American Society of Clinical Oncology

Christian G. Downs, JD, MHA, Executive Director, Association of Community Cancer Centers

8:20 – 9:15 AM          Billing and Coding in 2021

Teri Bedard, RT(R)(T), CPC, Executive Director, Client & Corporate Resources, Revenue Cycle Coding Strategies, Inc.

9:15 – 10:00 AM          Networking Break/Virtual Exhibit Hall

10:00 – 10:40 AM        Telemedicine Update

Chris Meyer, Director of Virtual Care and Telehealth, Marshfield Clinic Health System

Jeron Jackson, MHA, Service Line Administrator, Oncology and Musculoskeletal Service Lines, Marshfield Clinic Health System

10:40 – 11:15 AM         Fellows Research Presentation

Patrick Grogran, MD, University of Wisconsin

Joanna Zurko, MD, Medical College of Wisconsin

Reggie Thomes, DO, Gundersen Health System

11:15 AM – 12:00 PM        Molecular Hematology Clinical Update

Parameswaran Hari, MD, MS, Armand Quick William Stapp Professor of Hematology; Chief, Division of Hematology Oncology, Medical College of Wisconsin

12:00 PM                      Closing Remarks/Lunch/Exhibit Hall

Benjamin M. Parsons, DO, President, Wisconsin Association of Hematology and Oncology

A series of brief presentations about current, ongoing WON studies. Investigators to share study progress and updates. Investigators will present new concepts to solicit interest, garner enthusiasm, and field questions related to their study ideas.

1:00 - 1:05 PM          Welcome & Introductions

Ryan Mattinson, MD, Director, Wisconsin Oncology Network (WON)

1:10 – 1:20 PM          UW15068 UWCCC Molecular Tumor Board Registry

Mark Burkard, MD, University of Carbone Cancer Center

1:20 – 1:30 PM          UW16112 Phase II Study of Neoadjuvant Weekly Carboplatin/Paclitaxel Followed by Dose Dense AC in Patients with Triple Negative Non-Metastatic Breast Cancer

Yee Chung Cheng, MD, Medical College of Wisconsin

1:30 – 1:40 PM          UW16086 Bendamustine + Obinutuzumab Induction Chemoimmunotherapy with Risk Adapted Obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma

Julie Chang, MD, University of Wisconsin

1:40 – 1:50 PM          UW18131 A Phase II Study of Split-Dose R-CHOP in Older Adults with Diffuse Large B cell Lymphoma

Chris Fletcher, MD, University of Wisconsin

1:50 – 2:00 PM          UW19029 Phase 2 Trial of FOLFOX + Liposomal Irinotecan (+ Trastuzumab for Her2+) as a 1st Line Treatment of Metastatic Gastroesophageal Adenocarcinoma (GEA)

Nataliya Uboha, University of Wisconsin

2:00 – 2:10 PM          UW19046 A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients with ESR1 Mutations

Amy Fowler, MD, University of Wisconsin

2:10 – 2:20 PM          UW20037 A Phase II Trial of Onapristone in Combination with Fulvestrant for Women with ER-positive, PR-positive and HER2-Negative Metastatic Breast Cancer After Progression on Aromatase and CDK4/6 Inhibitors

Sailaja Kamaraju, MD, Medical College of Wisconsin

2:20 – 2:30 PM         Closing Remarks

Ryan Mattison, Director, Wisconsin Oncology Network (WON)

*Agenda as of 07.14.21 and subject to change.